Optimer Forges $90M Licensing Deal With Japan’s Astellas Pharma

San Diego-based biopharmaceutical company Optimer Pharmaceuticals Inc. stands to gain $90 million or more through an exclusive license it granted to Tokyo-based Astellas Pharma Inc. for the anti-infective drug fidaxomicin.